Clinical Trials Logo

Lymphoproliferative Disorder clinical trials

View clinical trials related to Lymphoproliferative Disorder.

Filter by:

NCT ID: NCT00869323 Terminated - Clinical trials for Lymphoproliferative Disorder

Bortezomib and Rituximab in Treating Patients With Post-Transplant Lymphoproliferative Disorders

Start date: March 2009
Phase: Phase 2
Study type: Interventional

RATIONALE: Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the cancer. Monoclonal antibodies, such as rituximab, can block cancer cell growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Giving bortezomib together with rituximab may kill more cancer cells. PURPOSE: This phase II trial is studying how well giving bortezomib together with rituximab works in treating patients with post-transplant lymphoproliferative disorders.

NCT ID: NCT00823524 Completed - Lymphoma Clinical Trials

Donor Natural Killer Cells After Donor Stem Cell Transplant in Treating Patients With Advanced Cancer

Start date: January 2009
Phase: Phase 1/Phase 2
Study type: Interventional

RATIONALE: Giving an infusion of natural killer cells from a donor after a donor stem cell transplant may help kill any remaining cancer cells after the transplant. PURPOSE: This phase I/II trial is studying the side effects and best dose of donor natural killer cells when given after a donor stem cell transplant in treating patients with advanced cancer.

NCT ID: NCT00750009 Completed - Lymphoma Clinical Trials

Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical Trial

Start date: April 2008
Phase: Phase 3
Study type: Interventional

RATIONALE: Providing information that is tailored to answer patients' questions about clinical trials may help patients with cancer decide to enroll in a clinical trial. It is not known whether providing personalized information is more effective than basic information in helping patients make decisions about clinical trials. PURPOSE: This randomized phase III trial is studying personalized information to see how well it works compared with basic information in helping patients make decisions about participating in a clinical trial.

NCT ID: NCT00734890 Completed - Lung Cancer Clinical Trials

Vandetanib and Bevacizumab in Treating Patients With Advanced Solid Tumors or Lymphoma

Start date: March 2008
Phase: Phase 1
Study type: Interventional

RATIONALE: Vandetanib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as bevacizumab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Bevacizumab and vandetanib may also stop the growth of cancer cells by blocking blood flow to the cancer. Giving vandetanib together with bevacizumab may kill more cancer cells. PURPOSE: This phase I trial is studying the side effects and best dose of vandetanib and bevacizumab in treating patients with advanced solid tumors or lymphoma.

NCT ID: NCT00726830 Terminated - Pain Clinical Trials

Methadone, Morphine, or Oxycodone in Treating Pain in Patients With Cancer

Start date: March 2009
Phase: N/A
Study type: Interventional

RATIONALE: Methadone, morphine, or oxycodone may help relieve pain caused by cancer. It is not yet known whether methadone is more effective than morphine or oxycodone in treating pain in patients with cancer. PURPOSE: This randomized clinical trial is studying methadone to see how well it works compared with morphine or oxycodone in treating pain in patients with cancer.

NCT ID: NCT00719563 Completed - Lymphoma Clinical Trials

American Ginseng in Treating Patients With Fatigue Caused by Cancer

Start date: October 2008
Phase: Phase 3
Study type: Interventional

RATIONALE: American ginseng may reduce fatigue in patients with cancer. It is not yet known whether American ginseng is more effective than a placebo in treating cancer-related fatigue. PURPOSE: This randomized phase III trial is studying American ginseng to see how well it works in treating patients with fatigue caused by cancer.

NCT ID: NCT00666211 Completed - Pain Clinical Trials

Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain

Start date: May 2005
Phase: Phase 3
Study type: Interventional

RATIONALE: An Opioid Titration Order Sheet that allows healthcare providers to adjust the dose and schedule of pain medication may help improve pain treatment for patients with cancer. It is not yet known whether the use of an Opioid Titration Order Sheet is more effective than standard care in treating pain caused by cancer. PURPOSE: This randomized phase III trial is studying an Opioid Titration Order Sheet to see how well it works compared with standard care in treating patients with cancer pain.

NCT ID: NCT00661999 Completed - Lymphoma Clinical Trials

Darbepoetin Alfa With or Without Iron in Treating Anemia Caused By Chemotherapy in Patients With Cancer

Start date: January 2006
Phase: Phase 3
Study type: Interventional

RATIONALE: Darbepoetin alfa may cause the body to make more red blood cells. Red blood cells contain iron that is needed to carry oxygen to the tissues. It is not yet known whether giving darbepoetin alfa (DA) together with intravenous iron or oral iron is more effective than giving darbepoetin alfa together with a placebo in treating anemia caused by chemotherapy. PURPOSE: This randomized phase III trial is studying giving darbepoetin alfa together with iron to see how well it works compared with giving darbepoetin alfa together with a placebo in treating anemia caused by chemotherapy in patients with cancer.

NCT ID: NCT00646139 Completed - Lymphoma Clinical Trials

KX2-391 in Treating Patients With Advanced Solid Tumors or Lymphoma That Did Not Respond to Treatment

Start date: October 2007
Phase: Phase 1
Study type: Interventional

RATIONALE: KX2-391 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase I trial is studying the side effects and best dose of KX2-391 in treating patients with advanced solid tumors or lymphoma that did not respond to treatment.

NCT ID: NCT00621036 Withdrawn - Lymphoma Clinical Trials

Vaccine Therapy and GM-CSF in Treating Patients With CNS Lymphoma

Start date: October 19, 2007
Phase: Phase 2
Study type: Interventional

RATIONALE: Vaccines made from a person's cancer proteins may help the body build an effective immune response to kill cancer cells. Colony-stimulating factors, such as GM-CSF, may increase the number of immune cells found in bone marrow or peripheral blood. Giving vaccine therapy together with GM-CSF may make a stronger immune response and kill more cancer cells. PURPOSE: This phase II trial is studying the side effects and how well giving vaccine therapy together with GM-CSF works in treating patients with CNS lymphoma.